Top Section/Ad
Top Section/Ad
Most recent
DocMorris announces Sfr200m rights issue expected in May
Stock drops 17% in highly volatile market
Deal follows steep share price fall
More articles/Ad
More articles/Ad
More articles
-
Idorsia, the Swiss biotech company, has turned to the convertible bond market to finance looming product launches and the development of its late-stage drug pipeline. -
Chinese biopharmaceutical company I-Mab is moving ahead with plans for a dual listing in Shanghai, as it looks to broaden its investor base.
-
Hong Kong’s stock exchange has rejected an IPO application from Aim Vaccine, a leading Chinese vaccine maker. The deal is being sponsored by China Securities, CICC, Goldman Sachs and Macquarie.
-
Pharmaceutical ingredients manufacturer Glenmark Life Sciences is set to launch a Rp15.1bn ($202.6m) IPO on Tuesday.
-
McLaren, the sports car manufacturer, closed its $620m five year deal with a 7.5% coupon on Thursday after investors piled into the order book.
-
A leading shareholder in WuXi Biologics (Cayman) has pocketed HK$10.3bn ($1.3bn) after offloading a chunk of the company’s shares.
